| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Tranylcypromine HCl targets multiple enzymes and receptors. It is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/KDM1A), with an IC50 of 20.7 µM in a cell-free assay. It also irreversibly inhibits monoamine oxidase A (MAO-A) and MAO-B with IC50 values of 2.3 and 0.95 µM, respectively. Additionally, it inhibits CYP2A6 with Ki values of 0.08 µM and 0.2 µM in cDNA-expressing microsomes and human liver microsomes, respectively. By inhibiting LSD1, it prevents histone demethylation, thereby modulating gene expression. Inhibition of MAO prevents the breakdown of monoamine neurotransmitters, contributing to its antidepressant effects.
|
|---|---|
| ln Vitro |
Human primary keratinocytes transduced by two factors, Oct4 and Klf4, undergo reprogramming when Tranylcypromine (SKF 385) (GMP) and Laduviglusib are combined [2].
In vitro, Tranylcypromine HCl is an irreversible inhibitor of LSD1 with an IC50 of 20.7 µM. It inhibits MAO A and MAO B with IC50 values of 2.3 and 0.95 µM, respectively. It also inhibits CYP2A6 with Ki values of 0.08 µM and 0.2 µM in cDNA-expressing microsomes and human liver microsomes, respectively. These in vitro studies confirm its multi-target mechanism of action. The compound is used as a tool to study histone demethylation and monoamine oxidase inhibition in various cell-based and biochemical assays. |
| ln Vivo |
In wild-type mice, tranylcypromine hydrochlorid (3 mg/kg; intraperitoneal; once daily for three days) reduces proinflammatory cytokine COX-2 and IL-6 levels as well as LPS-mediated microglial activation[3]. In 5xFAD mice, tranylcypromine hydrochlorid (3 mg/kg; intraperitoneal; once daily for 7 days) reduces Aβ-mediated microglial activation[3].
In vivo, Tranylcypromine HCl is an irreversible inhibitor of MAO and LSD1. It has been used clinically as an antidepressant due to its ability to inhibit MAO, thereby increasing the levels of monoamine neurotransmitters in the brain. Its inhibition of LSD1 has also been studied for potential therapeutic applications in cancer and other diseases. The compound is orally active and crosses the blood-brain barrier, allowing it to exert its effects on the central nervous system. Its clinical use is limited due to its side effect profile, including hypertensive crisis. |
| Enzyme Assay |
Non-cellular enzyme assays for Tranylcypromine HCl typically involve measuring its inhibition of MAO or LSD1 activity. For MAO inhibition, assays use purified MAO A or MAO B enzyme and a fluorogenic or radiometric substrate, such as kynuramine or serotonin, to measure the rate of enzymatic reaction in the presence of varying concentrations of the compound. For LSD1 inhibition, assays use purified LSD1 enzyme and a histone H3 peptide substrate to measure demethylation activity. IC50 values are determined from dose-response curves. These assays are essential for characterizing its potency and selectivity.
|
| Cell Assay |
In vitro cell-based assays for Tranylcypromine HCl are conducted using cancer cell lines or neuronal cell cultures to assess its effects on histone demethylation, gene expression, and cell proliferation. Cells are treated with the compound, and changes in histone H3K4me2 methylation levels are measured by Western blotting or immunofluorescence. Cell viability and proliferation are assessed using MTT or similar assays. These experiments are crucial for confirming its mechanism of action at the cellular level and for identifying its potential therapeutic applications.
|
| Animal Protocol |
Animal/Disease Models: Wild-type mice[3]
Doses: 3 mg/kg Route of Administration: intraperitoneal (ip)injection; 3 mg/kg one time/day for 3 days Experimental Results: Dramatically down-regulated LPS-stimulated microglial activation in the cortex and Hippocampus, and LPS-induced astrocyte activation only in the cortex. decreased LPS-induced COX-2 levels in hippocampus CA1, diminished LPS-evoked IL-6 levels in the cortex and hippocampus CA1 and suppressed LPS-mediated IL-1β levels in the cortex. Animal/Disease Models: 5xFAD mice[3] Doses: 3 mg/kg Route of Administration: intraperitoneal (ip)injection; 3 mg/kg one time/day for 7 days Experimental Results: Differentially regulated microglial and astrocyte activation in this mouse model of AD. In vivo animal studies for Tranylcypromine HCl are typically conducted in rodent models of depression or cancer to evaluate its efficacy. For depression models, the compound is administered orally or intraperitoneally, and behavioral tests such as the forced swim test or tail suspension test are used to assess antidepressant-like effects. For cancer models, tumor-bearing mice are treated with the compound, and tumor growth is monitored. These studies are essential for validating its in vivo efficacy and for understanding its pharmacological profile. |
| ADME/Pharmacokinetics |
Tranylcypromine HCl is an orally active compound with a molecular weight of 169.66 g/mol. It is well-absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Its pharmacokinetic properties have been studied in clinical settings. It is metabolized in the liver and excreted by the kidneys. Its half-life and other pharmacokinetic parameters are available from clinical studies. It is a prescription drug for the treatment of depression.
|
| Toxicity/Toxicokinetics |
Tranylcypromine HCl has an established safety profile from its clinical use as an antidepressant. Common side effects include dizziness, insomnia, and gastrointestinal disturbances. As a non-selective MAO inhibitor, it carries a risk of hypertensive crisis when combined with tyramine-rich foods or other serotonergic drugs. Comprehensive toxicological data are available from its clinical use. Tranylcypromine HCl is an approved drug for the treatment of depression.
|
| References |
Drug Metab Dispos.2001 Jun;29(6):897-902;Environ Health Perspect.2004 Aug;112(11):1159-64.
|
| Additional Infomation |
(1R,2S)-transphenylcyclopropylamine hydrochloride is a hydrochloride salt prepared by reacting (1R,2S)-transphenylcyclopropylamine with an equivalent amount of hydrochloric acid. It contains (1R,2S)-transphenylcyclopropylamine (1+). It is the enantiomer of (1S,2R)-transphenylcyclopropylamine hydrochloride.
See also: transphenylcyclopropylamine (note moved to). Tranylcypromine HCl (SKF 385 hydrochloride) is an irreversible inhibitor of LSD1, MAO A, and MAO B. It inhibits LSD1 with an IC50 of 20.7 µM, MAO A with an IC50 of 2.3 µM, and MAO B with an IC50 of 0.95 µM. It is used in the research of depression and as a tool for studying histone demethylation. Tranylcypromine HCl is an approved antidepressant and is also available as a research compound. |
| Molecular Formula |
C9H12CLN
|
|
|---|---|---|
| Molecular Weight |
169.65
|
|
| Exact Mass |
169.065
|
|
| CAS # |
1986-47-6
|
|
| Related CAS # |
|
|
| PubChem CID |
2723716
|
|
| Appearance |
White to yellow solid powder
|
|
| Boiling Point |
218.3ºC at 760mmHg
|
|
| Melting Point |
162-169ºC(lit.)
|
|
| Flash Point |
90.8ºC
|
|
| Vapour Pressure |
0.127mmHg at 25°C
|
|
| LogP |
3.003
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
1
|
|
| Rotatable Bond Count |
1
|
|
| Heavy Atom Count |
11
|
|
| Complexity |
116
|
|
| Defined Atom Stereocenter Count |
2
|
|
| SMILES |
C1[C@H]([C@@H]1N)C2=CC=CC=C2.Cl
|
|
| InChi Key |
ZPEFMSTTZXJOTM-OULXEKPRSA-N
|
|
| InChi Code |
InChI=1S/C9H11N.ClH/c10-9-6-8(9)7-4-2-1-3-5-7;/h1-5,8-9H,6,10H2;1H/t8-,9+;/m0./s1
|
|
| Chemical Name |
trans-2-Phenylcyclopropylamine Hydrochloride
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.74 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.74 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (14.74 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.8945 mL | 29.4724 mL | 58.9449 mL | |
| 5 mM | 1.1789 mL | 5.8945 mL | 11.7890 mL | |
| 10 mM | 0.5894 mL | 2.9472 mL | 5.8945 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT01430455 | Completed Has Results | Drug: Tranylcypromine | Bipolar Disorder I or II | New York State Psychiatric Institute | November 2011 | Phase 4 |
| NCT00653393 | Completed | Drug: Tranylcypromine Drug: Parnate |
To Determine the Bioavailability of Tranylcypromine |
Par Pharmaceutical, Inc. | October 2004 | Phase 1 |
| NCT00296686 | Terminated | Drug: Tranylcypromine Drug: Dextroamphetamine |
Major Depression | New York State Psychiatric Institute | September 2001 | Phase 4 |
| NCT02273102 | Completed | Drug: Tranylcypromine Drug: Tretinoin |
Acute Myelogenous Leukemia Myelodysplastic Syndromes |
University of Miami | March 2, 2015 | Phase 1 |
|
|---|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
